For example, in murine NASH-HCC models unresponsive to anti-PD-1 therapy, co-treatment with a CXCR2 inhibitor (to prevent neutrophil recruitment) restored T-cell infiltration and tumor control [28,29]. Here, CXCR2 is linked to metabolic dysfunction-associated steatohepatitis.